摘要
目的观察复方甘草酸单胺(美能)在辅助治疗复治肺结核并存慢性乙型肝炎的临床疗效与不良反应。方法将56例复治肺结核并存慢性乙型肝炎者随机分为治疗组与对照组,在两组均投予有效抗结核治疗基础上,治疗组27例,加用美能;对照组29例,投予还原型谷胱甘肽。结果治疗2个月时,治疗组肝功能改善总有效率88.9%,对照组为62.7%(P<0.05),治疗组临床症状和体征消失率、明显改善率分别为37.0%和59.3%,对照组为27.6%和44.8%,两者比较差异有统计学意义。加强期结束:治疗组病灶显吸率及痰菌阴转率分别为96.3%和95.6%,明显高于对照组的62.1%和48.0%。不良反应少。结论美能在复治肺结核并存慢性乙肝患者治疗过程中能有效改善肝功能,保障顺利完成抗结核全程化疗。
Results After two month＇s treatment, the total effective rate of liver function improvement was 88.9% in the treatment gruop, and 62.7% （P〈0.05） in the control group. The rate of clinical symptom and physical sign disappearance as well as distinct amelioration were respectively 37% and 59.3% in the treatment group, and for the control group 27.6% and 44.8%. Notable differences could be found in comparison between the treatment group and the control group in the above mentioned aspects. At the end of the enhanced treatment peri od, the rates of tuberculosis foci absorption and the negative sputum conversion were 93.6% and 95.6% in treatment group, which were much higher than those of the control group which were respectively 62.2% and 48. 0%. Adverse reactions were rarely found. Conclusion Stronger Neo-Minophagen C is effective and reliable in improving liver function and ensuring the success of the whole process of anti-tuberculosis chemotherapy for patients suffering from tuberculosis with retreated and Chronic Hepatitis B.
出处
《福建医药杂志》
CAS
2007年第3期3-6,共4页
Fujian Medical Journal
基金
福州市科技计划项目(2004-66)
